• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Weak HLA Antibody Levels Not Associated with Platelet Refractoriness

April 26, 2013

A study published in the journal Blood suggests that low to moderate levels of human leukocyte antigen (HLA) antibodies are not predictive of platelet transfusion failure. Among 530 participants from the Trial to Reduce Alloimmunization to Platelets (TRAP) study, 101 had developed plateletrefractoriness without evidence of HLA or human platelet antigen (HPA) antibodies, as detected by a lymphocytoxicity assay (LCA).  Researchers further evaluated HLA antibody levels among a subset of TRAP participants using longitudinal panel analysis with a more sensitive bead-based assay. Among 170 LCA-negative participants evaluated, HLA antibody levels were not significantly higher among those with clinical refractoriness than those without refractoriness. However, among 20 LCA-positive individuals, higher levels of HLA antibodies were significantly associated with clinical refractoriness. Levels of HPA antibody, as measured by a sensitive enzyme-linked immunosorbet assay, were not predictive of clinical refractoriness, among LCA-negative and LCA-positive patients.

Reference

1.    Jackman RP, Deng X, Bolgiano D, Lebedeva M, Heitman JW, Busch MP, Slichter SJ, Norris PJ. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013 121, 3261-3266.

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • AABB Issues Updated TRALI Risk Reduction Standards

  • Secondary Bacterial Culture for Platelets Reduces Transfusion Risk and Complies with FDA Draft Guidance for Platelet Safety

  • Revisiting Zika virus screening for donated blood

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Guidelines for Platelet Transfusion Recommend Restrictive Strategies

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley